Tempest Therapeutics, Inc. TPST
We take great care to ensure that the data presented and summarized in this overview for Tempest Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding TPST
View all-
Black Rock Inc. New York, NY550KShares$4.09 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA433KShares$3.22 Million0.0% of portfolio
-
Ubs Group Ag324KShares$2.41 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA298KShares$2.22 Million0.0% of portfolio
-
Susquehanna International Group, LLP Bala Cynwyd, PA115KShares$852,3180.0% of portfolio
-
Northern Trust Corp Chicago, IL99.4KShares$739,4690.0% of portfolio
-
Davenport & CO LLC50KShares$372,0000.0% of portfolio
-
Morgan Stanley New York, NY44.5KShares$330,8190.0% of portfolio
-
State Street Corp Boston, MA41.5KShares$308,7000.0% of portfolio
-
Advisor Group Holdings, Inc. Phoenix, AZ25.7KShares$191,3710.0% of portfolio
Latest Institutional Activity in TPST
Top Purchases
Top Sells
About TPST
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.
Insider Transactions at TPST
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 12
2024
|
Versant Venture Capital Vi, L.P. |
SELL
Open market or private sale
|
Direct |
387,999
-64.89%
|
$387,999
$1.1 P/Share
|
|
Aug 08
2024
|
Versant Venture Capital Vi, L.P. |
SELL
Open market or private sale
|
Direct |
400,000
-40.08%
|
$400,000
$1.35 P/Share
|
|
Jul 03
2024
|
Stephen R Brady President and CEO |
BUY
Open market or private purchase
|
Direct |
35,000
+43.01%
|
$70,000
$2.11 P/Share
|
|
Jul 02
2024
|
Samuel Whiting Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
4,672
+32.8%
|
$9,344
$2.13 P/Share
|
|
Jun 28
2024
|
Justin Trojanowski Corporate Controller |
BUY
Open market or private purchase
|
Direct |
7,500
+25.28%
|
$15,000
$2.16 P/Share
|
|
Apr 29
2022
|
Thomas Woiwode Director |
BUY
Open market or private purchase
|
Indirect |
2,118,644
+50.0%
|
$4,237,288
$2.36 P/Share
|
|
Jan 07
2022
|
Thomas W. Dubensky President |
BUY
Open market or private purchase
|
Direct |
2,000
+1.73%
|
$8,000
$4.78 P/Share
|
|
Jan 06
2022
|
Samuel Whiting Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
1,700
+47.21%
|
$6,800
$4.8 P/Share
|
|
Jun 25
2021
|
Samuel Whiting Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
201
+50.0%
|
-
|
|
Jun 25
2021
|
Pierre Lorenzo Corporate Controller |
BUY
Grant, award, or other acquisition
|
Direct |
53
+50.0%
|
-
|
|
Jun 25
2021
|
Thomas Woiwode Director |
BUY
Grant, award, or other acquisition
|
Indirect |
2,176,411
+50.0%
|
-
|
|
Jun 25
2021
|
Thomas W. Dubensky President |
BUY
Grant, award, or other acquisition
|
Direct |
111,343
+50.0%
|
-
|
|
Jun 25
2021
|
Stella Xu |
BUY
Grant, award, or other acquisition
|
Indirect |
579,710
+50.0%
|
-
|
Last 12 Months Summary
| Open market or private sale | 788K shares |
|---|